NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Immuneering Corporation (IMRX) Stock Analysis

Immuneering Corporation (IMRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IMRX

$4.82

−$0.22 (−4.37%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMRX with… →

IMRX Key Statistics

As of Sep 4, 2026
Trading
Open
$4.94
Previous Close
$5.04
Day's Range
4.81–5.00
52-Week Range
3.86–10.08
Volume
999.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.39
Valuation
Market Cap
$311.84M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.89
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$56.02M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
64.70M
1-Year Return
−11.72%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
1.01M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IMRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−26.75%
2025+199.09%
2024−70.07%
2023+51.55%
2022−70.01%
2021 (partial year)−8.07%

As of September 4, 2026.

IMRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$56.02M—
2024$0.00−$61.04M—
2023$0.00−$53.47M—
2022$316.95K−$50.51M−15937.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$59.38M−$56.02M—
2024$0.00—−$64.07M−$61.04M—
2023$0.00$0.00−$58.41M−$53.47M—
2022$316.95K$158.83K−$51.75M−$50.51M−15937.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IMRX Valuation vs Biotechnology Median

Median of 656 stocks
MetricIMRXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Immuneering Corporation (IMRX) carries a market capitalisation of $311.84M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 57.

The 52-week range on file runs from $3.86 to $10.08. The most recent close on file for IMRX is $4.82, dated September 4, 2026. That is −$0.22 (−4.37%) against the previous close. The latest close sits 24.87% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $56.02M. The reported profit margin is 0%. Trailing earnings per share are −0.89.

Across the 4 fiscal years on file, revenue moves from $316.95K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.39. Daily returns over the trailing 5 years annualize to a volatility of 112.35%. The trailing one-year price return is −11.72%. Measured over 5 years, that is −29.82% a year compounded.

Growth & Income

The record shows no dividend for IMRX.

So far in 2026 the price is −26.75%. Across the complete calendar years on file, 2025 returned +199.09% and 2024 returned −70.07%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Immuneering Corporation (IMRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Immuneering Corporation IMRX $311.84M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Immuneering Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Immuneering Corporation

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Visit website →